2-Day Online PV Audit Strategy Planning (Pharmacovigilance) Training – January 20-21, 2022 – ResearchAndMarkets.com | Business and finance

0


[ad_1]

DUBLIN – (BUSINESS WIRE) – Dec. 17 2021–

the “PV Audit Strategy Planning (Pharmacovigilance) – A Practical Approach to Design and Implementation” training has been added to ResearchAndMarkets.comoffer.

The European Medicines Agency (EMA) Good Pharmacovigilance Practice (GVP) Guideline, Module IV, requires risk-based quality system audits to be performed at regular intervals to ensure compliance. to established quality requirements and to determine its effectiveness. It includes an audit of the pharmacovigilance system which is covered by the quality system. The GVP modules are applicable to companies based in the EU and to any company marketing medicines on a global scale.

The legally required risk-based audit strategy should cover all PV processes and tasks undertaken or delegated to other departments, MAH affiliates and third parties such as distributors, external service providers, partners (the PV universe). The strategic PV audit plan is used to prepare the PV audit program, i.e. the annual PV audit schedule.

During this two-day workshop, we will review the EMA and FDA requirements for risk-based PV system and quality system audits.

The course will focus on the design of the PV audit strategy, the identification of PV processes and entities subject to PV audit (define the universe of PV audit), development of the assessment methodology risk management, the development of procedures / tools to monitor PV processes and activities, and the implementation of the PV audit strategic plan. In addition, we will examine the methods of quality monitoring and management of third parties performing photovoltaic activities.

Learning objectives:

By the end of this course, participants should be able to:

  • Understand the legal requirements and expectations of health authorities for a risk-based audit program and current interpretation. Plan, develop and implement the strategic PV audit plan, which includes the following processes:
    • Develop a high level PV audit strategy
    • Identify PV activities and processes subject to PV audit
    • Develop risk assessment criteria
    • Identify the universe of PV audit – entities subject to PV audit
    • Categorize the entities subject to the PV audit
    • Perform risk assessments
    • Prioritize the entities to be audited according to the relative risk
    • Prepare a 3 to 5 year PV audit plan
  • Identify procedures / tools to monitor third party PV quality

Main topics covered:

Day 01 (9:30 a.m. – 4:30 p.m. EST)

  • 9:30 am: Beginning of the session
  • Review of FDA and EMEA requirements for risk-based PV audits
  • The pharmacovigilance system and the quality system
  • Planning the audit at the strategic level
  • Practical exercises
  • PV activities and processes subject to PV audit
  • Risk assessment criteria
  • The world of PV audit – all entities subject to PV audit
  • Security data exchange agreements (SDEA) and supplier contracts

Day 02 (9:30 a.m. – 4:30 p.m. EST)

  • Stability studies (shelf life)
  • Categorization of entities (PV Audit Universe)
  • Risk assessments
  • Prioritization of entities to be audited according to relative risk
  • 3 to 5 year PV audit plan
  • Practical exercises
  • Procedural documents, for example SOP
  • Identify procedures / tools to monitor PV quality for third party monitoring
  • Questions and answers

For more information on this training, visit https://www.researchandmarkets.com/r/8ooljy

View source version on businesswire.com:https://www.businesswire.com/news/home/20211217005261/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Director

[email protected]

For EST office hours, call 1-917-300-0470

For USA / CAN call toll free 1-800-526-8630

For GMT office hours, call + 353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH

SOURCE: Research and markets

Copyright Business Wire 2021.

PUB: 12/17/2021 07:35 / DISC: 12/17/2021 07:36

http://www.businesswire.com/news/home/20211217005261/en

Copyright Business Wire 2021.

[ad_2]

Share.

About Author

Comments are closed.